What's Next For Seattle Genetics?

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

It’s Wednesday, Jan. 10, 2018, and Clay Siegall, Ph.D., and I are engaged in small talk, recalling when we both worked at Bristol-Myers Squibb and were the beneficiaries of “Team Shares,” a companywide stock-option program initiated in 1994. We’re in San Francisco for the annual J.P. Morgan Healthcare Conference (JPM), and Siegall, president, CEO, and chairman of Seattle Genetics, has agreed to meet me for an interview in this quiet second-floor space at the Kimpton Sir Francis Drake Hotel.

Our casual conversation continues until the ding-ding-ding of a cable car bell from the street below bursts through the room’s cracked window, reminding me that our time is short, and that I’m not here to simply reminisce about the “good old days.” Siegall and his company have been in the spotlight lately, especially with rumors swirling that its lead compound, ADCETRIS, might become a blockbuster. I’m here to find out how the company got to this point — and probably more importantly — what the future holds.